Lead sponsor
ProGen. Co., Ltd.
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
3
Trials led
2
Active
326
Total enrollment
15
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
2
Trials by status
Not yet recruiting
1
Active, not recruiting
1
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesHbA1c 7-10%Ph 2Active, not recruiting144
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.BMI 18-30Ph 1Completed102
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes MellitusBMI 25-40Ph 2Not yet recruiting80